Purpose: The present study examined the efficacy and safety of a lower rhPTH(1-84) dose.
INTRODUCTION
Hypoparathyroidism is a rare endocrine disorder of inappropriately low or absent circulating levels of parathyroid hormone (PTH), resulting in hypocalcemia and, in some patients, hyperphosphatemia. 1, 2 Conventional therapy, which may require the use of high doses of oral calcium and active vitamin D, can result in inadequate control of serum calcium and increased risk of complications, including hypercalciuria, nephrolithiasis and impaired renal function, soft-tissue calcification, bone structural abnormalities, and impaired quality of life. [3] [4] [5] [6] In addition, these supplements do not replace the missing hormone, which may have salutary effects of its own.
Recombinant human PTH (rhPTH , PTH recombinant DNA; Shire-NPS Pharmaceuticals Inc, Lexington, Massachusetts) is approved as adjunctive treatment of adults with chronic hypoparathyroidism. 7, 8 In the Phase III REPLACE study, 53% of patients receiving rhPTH(1-84) as once-daily subcutaneous (SC) injections at flexible doses of 50, 75, or 100 μg/d met the primary study end point (≥50% reduction from baseline in oral calcium and active vitamin D doses with maintenance of normal albumincorrected serum calcium) compared with only 2% of patients receiving placebo. 9 The lowest starting dose in this trial was 50 μg/d of rhPTH . However, the REPLACE data suggested that some patients might meet end points with a dose of rhPTH(1-84) lower than 50 μg/d. The objective of the 8-week RELAY clinical trial was, therefore, to assess the efficacy and safety of rhPTH(1-84) at fixed doses of 25 and 50 μg/d for the treatment of adult patients with hypoparathyroidism. The RELAY study was not intended to compare the 2 dose regimens with each other but rather to determine whether these 2 low doses of rhPTH(1-84) can be used successfully in some patients with hypoparathyroidism.
METHODS
The RELAY study was a Phase III, randomized, doseblinded, fixed-dose study in patients with hypoparathyroidism conducted at 11 sites in the United States. Eligible patients were aged 18 to 85 years, were provided written informed consent forms, had a history of well-documented hypoparathyroidism for ≥18 months, had not received rhPTH(1-84) or rhPTH (1-34) within 4 weeks of randomization, could selfadminister into thigh daily SC injections of study medication, had a serum creatinine level of 132.6 µmol/L, required calcitriol ≥0.25 μg/d and oral calcium ≥1000 mg/d above the normal dietary calcium intake, had total serum calcium levels less than or equal to the upper limit of normal (ULN) based on local laboratory results, and had serum 25-hydroxyvitamin D ≤1.5 times the ULN within 16 weeks of enrollment. Patients with hypoparathyroidism resulting from an activating mutation in the calcium-sensing receptor gene or impaired responsiveness to PTH (pseudohypoparathyroidism) were excluded from this study. In addition, women who were pregnant or lactating were excluded, as were patients with any condition that, in the opinion of the investigator, would preclude them from complying with study requirements or completing the study. Patients were randomized to receive either 25 or 50 µg/d of rhPTH(1-84) in a 1:1 allocation ratio and stratified by the patient's calcium source (carbonate and citrate). The true randomization scheme was generated by the independent randomization statistician and provided to and maintained by the investigator. On day 1, patients were assigned a kit number from the randomization list starting from the top of the list and moving down sequentially through the list for each subsequent patient. All doses of study drug for each patient were to be taken from the kit designated for that patient. Blinding was accomplished by supplying each patient with 2 injection pen devices and 1 cartridge kit containing 8 cartridges. Each dual-chamber cartridge was designed to deliver 14 blinded doses, each dose containing 25 or 50 μg of rhPTH(1-84). All patients self-administered rhPTH (1-84) for 8 weeks via SC injection into alternating thighs daily. During the study, patients continued to receive the same oral calcium (carbonate or citrate) supplement they had received before entering the study. Sufficient supplemental native vitamin D was administered to maintain each patient's serum 25-hydroxyvitamin D level within the normal range; doses ranged from 400 to 10,000 IU/d. Investigators were permitted to down-titrate oral calcium and active vitamin D (calcitriol) doses based on total serum calcium levels (measured 3-5 days after dose adjustments) and patient-reported symptoms. Following a titration guideline, the calcitriol dose was reduced first by up to 50%, and then the oral calcium dose was reduced by up to 50%. The study was conducted in accordance with applicable International Council for Harmonisation Guidelines, Good Clinical Practice, and the World Medical Association Declaration of Helsinki and its amendments. The study was reviewed and approved by central and local institutional review boards.
The primary efficacy end point of this study was the proportion of patients at week 8 who achieved a reduction in oral calcium supplement dose to ≤500 mg/d and a reduction in calcitriol supplement dose to ≤0.25 μg/d, while maintaining an albumincorrected total serum calcium level between 1.875 mmol/L and the ULN. The secondary efficacy end point was the proportion of patients at week 8 who achieved ≥50% reductions from baseline in both calcium and calcitriol doses and an albumin-corrected total serum calcium concentration that was normalized or maintained compared with the baseline value (≥1.875 mmol/L) and did not exceed the ULN for the central laboratory range. Note that the secondary end point is the same as the primary end point used in the 24-week REPLACE study. 9 The purpose of this study was to assess the efficacy and safety of 2 low fixed doses (25 and 50 μg/d) of rhPTH(1-84) in adult patients with hypoparathyroidism; 50 μg/d of rhPTH(1-84) was the starting dose in the REPLACE study. 9 The study was not intended to determine whether the 25-μg/d dose was superior or noninferior to the 50-μg/d dose. Therefore, the sample size was not calculated based on statistical assumptions. SAS software, version 9.1 (SAS Institute Inc, Cary, North Carolina) was used for all statistical procedures; statistical testing was performed using the 2-sided Fisher exact test, and 95% CI was provided for each group. The primary efficacy outcome was based on the intent-to-treat population, defined as all randomized patients who received ≥1 dose of rhPTH(1-84) and had ≥1 efficacy measurement. The secondary efficacy outcome was based on the per-protocol population, which was a subset of the intent-to-treat population with no significant protocol violations. Efficacy end points based on calcium and calcitriol supplementation were derived using investigator-prescribed and subject diary data; however, the investigatorprescribed data were considered the primary analysis and are the data presented here. The safety analyses were based on the safety population and included all patients who received ≥1 dose of study drug with any follow-up information. Adverse events were coded using Medical Dictionary for Regulatory Activities, version 13.0.
RESULTS
Forty-two patients were enrolled in the study; 41 patients (98%) completed the study. One patient in the rhPTH(1-84) 25-μg group discontinued from the study on day 38 owing to an adverse event (arthralgia), which was deemed by the investigator to be unrelated to treatment with the study drug. Patient demographic and baseline characteristics are summarized in Table I . At week 8, the primary efficacy end point was achieved by 4 patients (21%; 95% CI, 6%-46%) in the rhPTH(1-84) 25-μg group and 6 patients (26%; 95% CI, 10%-48%) in the 50-μg group (Figure 1) . The secondary efficacy end point at week 8 was achieved by 2 patients (11%; 95% CI, 1%-33%) in the 25-μg group and 6 patients (26%; 95% CI, 10%-48%) in the 50-μg group (Figure 1 The mean percentage changes from baseline at week 8 in the calcitriol dose were -3% and -39% in the 25-μg and 50-μg groups, respectively. This larger decrease in the higher-dose group was significantly different from the lower-dose effect (P ¼ 0.05).
Treatment-emergent adverse events (TEAEs) were experienced by 11 of 19 patients (58%) in the 25-μg group and 17 of 23 patients (74%) in 50-μg group. TEAEs reported in 42 patients in either group included paresthesia, headache, muscle spasms, and nausea (Table II) . TEAEs were reported as mild or moderate in severity by 10 of 11 patients (91%) in the 25-μg group and 17 of 17 patients (100%) in the 50-μg group; no serious TEAEs were reported during the study. In both groups, most TEAEs were judged by the investigator to be unrelated to treatment (9 of 11 [82%] in the 25-μg group and 13 of 17 [76%] in the 50-μg group).
DISCUSSION
In this limited, 8-week, randomized, dose-blinded study in which patients with hypoparathyroidism received rhPTH(1-84) at fixed doses of 25 or 50 μg/d, the primary efficacy end point was met by 21% of patients in the 25-μg group and 26% of patients in the 50-μg group. Overall, 11% of patients in the 25-μg group and 26% of patients in the 50-μg group met the secondary efficacy end point (which was identical to the primary efficacy end point used in the larger registration REPLACE trial). As was anticipated and borne out by the results, the proportion of patients who met the primary or secondary end point was relatively small. Nevertheless, this trial demonstrates that for a small number of patients with hypoparathyroidism, a dose as low as 25 μg/d can serve as a sufficient regimen. After 8 weeks of rhPTH(1-84), the oral calcium dose was reduced by 7% and 10% and the calcitriol dose was reduced by 3% and 39% in patients receiving 25 and 50 μg/d of rhPTH(1-84), respectively. In REPLACE, where flexible dosing was central to the study design, 21% of patients in the rhPTH(1-84) treatment arm completed the study at a dose of 50 µg/d, with the remainder of the group requiring higher doses (75 µg/d, 27%; 100 µg/d, 52%). 9 The findings from the REPLACE and RELAY studies suggest that although doses ≤50 µg/d of rhPTH(1-84) may be suitable for some patients, they will not be sufficient for most patients. Nevertheless, it is also evident that some patients can be managed successfully on these relatively low doses of rhPTH . Both dosages of rhPTH(1-84) were well tolerated throughout the study, with no reported serious TEAEs or unexpected safety events. TEAEs were experienced by 58% of patients in the 25-μg group and 74% in the 50-μg group; by comparison, in the placebo-controlled, flexible rhPTH(1-84) dose (50, 75, or 100 μg/d) REPLACE study, 93% of patients in the rhPTH(1-84) group and 100% of patients in the placebo group had at least one TEAE during the study (ie, from first day of dose through 4-week postdose follow-up). 9 Several factors limit interpretation of the results of this study, including the small sample size and lack of a placebo control group. In addition, despite randomization, the difference in baseline oral calcium and calcitriol supplement doses were significantly lower in the 25-μg group than the 50-μg group (P ¼ 0.038 and 
